Oculis Holding AG (OCS) Interest & Investment Income (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Interest & Investment Income of $468660.7 in Q1 2026, down 78.84% quarter-over-quarter from $2.2 million in Q4 2025, and down 14.53% on a YoY basis from $548339.5 in Q1 2025.
Oculis Holding AG (OCS) Interest & Investment Income (2021 - 2026) Analysis & Trends
Oculis Holding AG's Interest & Investment Income history runs 6 years deep, the most recent figure standing at $468660.7 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 14.53% year-over-year to $468660.7; the TTM figure through Mar 2026 stood at $468660.7 (down 14.53% YoY), while the FY2025 annual figure was $2.2 million, down 10.52% from the prior year.
- Interest & Investment Income was $468660.7 for Q1 2026 at Oculis Holding AG, down from $2.2 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.1 billion in Q3 2024 to a low of $8306.3 in Q2 2022.
- Historically, Interest & Investment Income has averaged $243.8 million across 5 years, with a median of $770397.7 in 2024.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income soared 236899.5% in 2024, then declined 17.62% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $130790.8 in 2022, then surged by 1131.73% to $1.6 million in 2023, then jumped by 53.62% to $2.5 million in 2024, then decreased by 10.52% to $2.2 million in 2025, then plunged by 78.84% to $468660.7 in 2026.
- The last three Interest & Investment Income figures came in at $468660.7 (Q1 2026), $2.2 million (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -14.79 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 468,660.72 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,660.72 |
| Dec 31, 2025 | 2.21 Mn |
| Sep 30, 2025 | 1.81 Bn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 548,339.51 |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.07 Bn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 665,641.42 |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 875,153.93 |
| Jun 30, 2023 | 281,380.41 |
| Mar 31, 2023 | 35,678.37 |
| Dec 31, 2022 | 130,790.76 |
| Sep 30, 2022 | 72,481.96 |
| Jun 30, 2022 | 8,306.34 |
| Dec 31, 2021 | 22,774.54 |